American Superconductor vs Aspen Aerogels
AMSC and ASPN side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMSC and ASPN compare
American Superconductor is the larger company, worth 2.6 times as much as Aspen Aerogels ($1.1B against $407M).
American Superconductor grew revenue faster over the last twelve months (25.9% versus −49.1% for Aspen Aerogels).
American Superconductor keeps more of each dollar of sales as profit, with a net margin of 42.6% compared with −62.4% at Aspen Aerogels.
American Superconductor scores higher on the StockData Score (12 against 4 for Aspen Aerogels), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMSC | ASPN |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $407M |
| Share price | $22.16 | $4.90 |
| Change, 1 year | −34.7% | 59.1% |
| Change, 5 years | 66.9% | −91.5% |
| Beta (5Y) | 1.69 | 2.62 |
| Employees | 1,195 | 854 |
| StockData Score | ||
| Total score | 12 (better) | 4 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 3 (better) | 0 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 7.3× | – |
| P/S | 3.3× | 2.0× (better) |
| P/B | 1.9× (better) | 2.1× |
| EV/EBITDA | 37.7× | – |
| P/FCF | 52.3× | 11.8× (better) |
| FCF yield | 1.9% | 8.5% (better) |
| Fair value | – | $4.59 |
| Margin of safety | – | −6.7% |
| Growth | ||
| Revenue growth (TTM) | 25.9% (better) | −49.1% |
| Revenue growth, 5Y average | 28.0% (better) | 22.0% |
| Net income growth (TTM) | 794% | – |
| EPS growth (TTM) | 677% | – |
| Profitability | ||
| Gross margin | 28.6% (better) | 2.7% |
| Operating margin | 4.9% (better) | −61.0% |
| Net margin | 42.6% (better) | −62.4% |
| FCF margin | 6.4% | 17.0% (better) |
| Return on equity | 30.2% (better) | −50.4% |
| Return on invested capital | 5.6% (better) | −84.3% |
| Financial health | ||
| Debt / equity | 0.00 | 0.12 (better) |
| Current ratio | 2.43 | 2.52 (better) |
| Altman Z-score | 2.52 (better) | −2.75 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 73.1% | 88.5% |
| Held by insiders | 3.5% | 16.8% |
| Insider net buying, 12 months | −$7.8M (better) | −$58.1M |
| Short interest, % of float | 9.1% | 9.3% |
Go deeper
- AMSC stock overview
- AMSC income statement
- AMSC valuation and score
- ASPN stock overview
- ASPN income statement
- ASPN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.